J Korean Med Sci.  2021 Dec;36(50):e338. 10.3346/jkms.2021.36.e338.

Formulating Hypotheses for Different Study Designs

• Misra DP
• Gasparyan AY
• Zimba O
• Yessirkepov M
• Agarwal V
• Kitas GD

• KMID: 2523560
• DOI: http://doi.org/10.3346/jkms.2021.36.e338

Abstract

Generating a testable working hypothesis is the first step towards conducting original research. Such research may prove or disprove the proposed hypothesis. Case reports, case series, online surveys and other observational studies, clinical trials, and narrative reviews help to generate hypotheses. Observational and interventional studies help to test hypotheses. A good hypothesis is usually based on previous evidence-based reports. Hypotheses without evidence-based justification and a priori ideas are not received favourably by the scientific community. Original research to test a hypothesis should be carefully planned to ensure appropriate methodology and adequate statistical power. While hypotheses can challenge conventional thinking and may be controversial, they should not be destructive. A hypothesis should be tested by ethically sound experiments with meaningful ethical and clinical implications. The coronavirus disease 2019 pandemic has brought into sharp focus numerous hypotheses, some of which were proven (e.g. effectiveness of corticosteroids in those with hypoxia) while others were disproven (e.g. ineffectiveness of hydroxychloroquine and ivermectin).

Keyword

Hypotheses; Research Ethics; Study Design; Pandemic

Figure

• 

  Fig. 1 Types of studies that help to generate and test hypotheses.

Reference

1. Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD. Scientific hypotheses: writing, promoting, and predicting implications. J Korean Med Sci. 2019; 34(45):e300. PMID: 31760713.

2. Misra DP, Agarwal V. Generating working hypotheses for original research studies. Cent Asian J Med Hypotheses Ethics. 2020; 1(1):14–19.

3. Misra DP, Zimba O, Gasparyan AY. Statistical data presentation: a primer for rheumatology researchers. Rheumatol Int. 2021; 41(1):43–55. PMID: 33201265.

4. Yessirkepov M, Gasparyan AY. Embracing social media for generating and testing hypotheses. Cent Asian J Med Hypotheses Ethics. 2021; 2(3):133–136.

5. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020; 382(10):929–936. PMID: 32004427.

6. Misra DP, Agarwal V. Systematic reviews: challenges for their justification, related comprehensive searches, and implications. J Korean Med Sci. 2018; 33(12):e92. PMID: 29542301.

7. Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int. 2011; 31(11):1409–1417. PMID: 21800117.

8. Röhrig B, du Prel JB, Wachtlin D, Blettner M. Types of study in medical research: part 3 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2009; 106(15):262–268. PMID: 19547627.

9. Misra DP, Agarwal V. Integrity of clinical research conduct, reporting, publishing, and post-publication promotion in rheumatology. Clin Rheumatol. 2020; 39(4):1049–1060. PMID: 32026178.

10. Smith GCS, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003; 327(7429):1459–1461. PMID: 14684649.

11. Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. BMJ. 1950; 2(4682):739–748. PMID: 14772469.

12. Goudsmit J. Alternative view on AIDS. Lancet. 1992; 339(8804):1289–1290. PMID: 1349680.

13. Duesberg P. Infectious AIDS--stretching the germ theory beyond its limits. Int Arch Allergy Immunol. 1994; 103(2):118–127. PMID: 8292899.

14. Dunlap RE, Jacques PJ. Climate change denial books and conservative think tanks: exploring the connection. Am Behav Sci. 2013; 57(6):699–731. PMID: 24098056.

15. Gupta L, Gasparyan AY, Misra DP, Agarwal V, Zimba O, Yessirkepov M. Information and misinformation on COVID-19: a cross-sectional survey study. J Korean Med Sci. 2020; 35(27):e256. PMID: 32657090.

16. Gupta L, Gasparyan AY, Zimba O, Misra DP. Scholarly publishing and journal targeting in the time of the coronavirus disease 2019 (COVID-19) pandemic: a cross-sectional survey of rheumatologists and other specialists. Rheumatol Int. 2020; 40(12):2023–2030. PMID: 33048199.

17. Parsonnet J. Clinician-discoverers--Marshall, Warren, and H. pylori . N Engl J Med. 2005; 353(23):2421–2423. PMID: 16339090.

18. Marshall B.. Helicobacter pylori--a Nobel pursuit? Can J Gastroenterol. 2008; 22(11):895–896. PMID: 19018331.

19. Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc Bayl Univ Med Cent. 2005; 18(1):21–25. PMID: 16200144.

20. Heymann DL, Wilder-Smith A. Successful smallpox eradication: what can we learn to control COVID-19? J Travel Med. 2020; 27(4):taaa090. PMID: 32478398.

21. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229):1033–1034. PMID: 32192578.

22. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020; 39(7):2055–2062. PMID: 32277367.

23. Misra DP, Gasparyan AY, Zimba O. Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates. Rheumatol Int. 2020; 40(11):1741–1751. PMID: 32880032.

24. Shah S, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). Int J Rheum Dis. 2020; 23(5):613–619. PMID: 32281213.

25. Kim AHJ, Sparks JA, Liew JW, Putman MS, Berenbaum F, Duarte-García A, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med. 2020; 172(12):819–821. PMID: 32227189.

26. Sattui SE, Liew JW, Graef ER, Coler-Reilly A, Berenbaum F, Duarte-García A, et al. Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert Rev Clin Immunol. 2020; 16(7):659–666. PMID: 32620062.

27. PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021; 397(10279):1063–1074. PMID: 33676597.

28. Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio Cuscó M, Ferrández O, Horcajada JP, et al. Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti Infect Ther. 2021; 19(2):147–163. PMID: 32853038.

29. Reardon S. Flawed ivermectin preprint highlights challenges of COVID drug studies. Nature. 2021; 596(7871):173–174. PMID: 34341573.

30. Butler-Laporte G, Nakanishi T, Mooser V, Morrison DR, Abdullah T, Adeleye O, et al. Vitamin D and COVID-19 susceptibility and severity in the COVID-19 host genetics initiative: a Mendelian randomization study. PLoS Med. 2021; 18(6):e1003605. PMID: 34061844.

31. The Lancet Diabetes Endocrinology. Vitamin D and COVID-19: why the controversy? Lancet Diabetes Endocrinol. 2021; 9(2):53. PMID: 33444566.

32. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021; 384(8):693–704. PMID: 32678530.

33. Khan FA, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021; 76(9):907–919. PMID: 33579777.

34. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10285):1637–1645. PMID: 33933206.

35. Sauvat A, Ciccosanti F, Colavita F, Di Rienzo M, Castilletti C, Capobianchi MR, et al. On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2. Cell Death Dis. 2020; 11(8):656. PMID: 32814759.

36. Tummino TA, Rezelj VV, Fischer B, Fischer A, O'Meara MJ, Monel B, et al. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. Science. 2021; 373(6554):541–547. PMID: 34326236.

37. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A. 2020; 117(30):17720–17726. PMID: 32647056.

38. Gasparyan AY, Misra DP, Yessirkepov M, Zimba O. Perspectives of immune therapy in coronavirus disease 2019. J Korean Med Sci. 2020; 35(18):e176. PMID: 32383371.

39. Portnov BA, Dubnov J, Barchana M. On ecological fallacy, assessment errors stemming from misguided variable selection, and the effect of aggregation on the outcome of epidemiological study. J Expo Sci Environ Epidemiol. 2007; 17(1):106–121. PMID: 17033679.

40. Zimba O, Gasparyan AY. Peer review guidance: a primer for researchers. Reumatologia. 2021; 59(1):3–8. PMID: 33707789.

41. Yessirkepov M, Gasparyan AY. From testable hypotheses to ethical papers and improved health service. Cent Asian J Med Hypotheses Ethics. 2020; 1(1):10–13.

42. Wiseman R, Watt C, Kornbrot D. Registered reports: an early example and analysis. PeerJ. 2019; 7:e6232. PMID: 30671302.

43. Gaur PS, Zimba O, Agarwal V, Gupta L. Reporting survey based studies - a primer for authors. J Korean Med Sci. 2020; 35(45):e398. PMID: 33230988.

44. Zimba O, Radchenko O, Strilchuk L. Social media for research, education and practice in rheumatology. Rheumatol Int. 2020; 40(2):183–190. PMID: 31863133.

45. Ng W. Preprints as medium for communicating new ideas, hypotheses, data, analysis and beyond. PeerJ Prepr. 2017; 5:e3154v1.

46. Smith CM. Origin and uses of primum non nocere--above all, do no harm! J Clin Pharmacol. 2005; 45(4):371–377. PMID: 15778417.